Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Slides:

Advertisements

Similar presentations

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Advertisements

Eri Hotta, Risa Tamagawa-Mineoka, Koji Masuda, Norito Katoh

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis is associated with lipid abnormalities at the onset of skin disease Lotus Mallbris, MD, PhD, Fredrik Granath, PhD, Anders Hamsten, MD, PhD,

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Expression of PD-L1 in mastocytosis

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis Federica Ricceri, MD, Leonardo.

Serum vitamin D status in adult patients with atopic dermatitis: Recommendations for daily practice Jorien van der Schaft, MD, PhD, Lieneke F.M. Ariens,

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD

Re-emergence of anti-topoisomerase I antibody with exacerbated development of skin sclerosis in a patient with systemic sclerosis Yasuhito Hamaguchi,

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Pilot study of a skin cancer education curriculum for medical students

Sirolimus for acute pemphigus vulgaris: A case report and discussion of dualistic action providing for both immunosuppression and keratinocyte protection

David M. Lemchak, DO, Oleg E. Akilov, MD, PhD

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Characterization of disease burden, comorbidities, and treatment use in a large, US- based cohort: Results from the Corrona Psoriasis Registry Bruce Strober,

Reply to: “A note on normality”

Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis Tsung-Yu Tsai, MD, Yu-Chen Huang, MD Journal.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss Elise A. Olsen, MD, Douglas Canfield, BS Journal.

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity James P. Strassner, BS, Mehdi Rashighi, MD, Maggi.

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Topical tacrolimus for chronic actinic dermatitis

Expression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinra Emmanuelle Amazan, MD, Khaled Ezzedine,

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Anjali Shroff, MD, Emma Guttman-Yassky, MD, PhD JAAD Case Reports

Stefan Tukaj, PhD, Detlef Zillikens, MD, Michael Kasperkiewicz, MD

Medicaid acceptance among pediatric dermatologists

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Oral allergy syndrome and contact urticaria to apples

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Jennifer L. Hundley, MD, Christie L

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Psoriasis localized exclusively to peristomal skin

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Jose Fernández-Vozmediano, PhD, Jose Armario-Hita, MD

Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo Rehan Khan, MSc,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Interrupting IL-6–receptor signaling improves atopic dermatitis but associates with bacterial superinfection Alexander A. Navarini, MD, PhD, Lars E.

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD, Norito Katoh, MD, PhD Journal of the American Academy of Dermatology Volume 70, Issue 5, Pages 882-888 (May 2014) DOI: 10.1016/j.jaad.2014.01.867 Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Serum levels of interleukin (IL)-33 in patients with atopic dermatitis (AD) (n = 62), patients with chronic idiopathic urticaria (n = 35), patients with psoriasis (n = 18), and healthy control subjects (n = 22). IL-33 levels were measured by enzyme-linked immunosorbent assay. Journal of the American Academy of Dermatology 2014 70, 882-888DOI: (10.1016/j.jaad.2014.01.867) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Relationship between serum levels of interleukin (IL)-33 and Eczema Area and Severity Index (EASI) scores in patients with atopic dermatitis (AD) (n = 62), and the receiver operating characteristic curve establishing cut-off levels between patients with moderate and severe AD for serum IL-33 levels (n = 50). AUC, Area under curve. Journal of the American Academy of Dermatology 2014 70, 882-888DOI: (10.1016/j.jaad.2014.01.867) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Relationship between serum levels of interleukin (IL)-33 and skin symptom severity scores for the most affected skin in patients with atopic dermatitis (n = 62). Journal of the American Academy of Dermatology 2014 70, 882-888DOI: (10.1016/j.jaad.2014.01.867) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Changes in Eczema Area and Severity Index (EASI) scores and serum levels of interleukin (IL)-33 before and after treatment in paired samples obtained from 10 patients with atopic dermatitis. Journal of the American Academy of Dermatology 2014 70, 882-888DOI: (10.1016/j.jaad.2014.01.867) Copyright © 2014 American Academy of Dermatology, Inc. Terms and Conditions